We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

South Africa's Competition Commission investigates Novo Nordisk and Sanofi for potential anti-competitive practices in the insulin pen market.

Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that ...

The plant will make three types of insulin, which Civica has pledged to sell for $30 a vial and $55 for a box of five pens. In 2023, Civica struck a deal to produce insulin for the state of California ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

The last few years have been tough for the insulin market, with recent policies and high-level pressure forcing companies to ...

Brazil's National Health Surveillance Agency (Anvisa) has approved the drug Awiqli, produced by the pharmaceutical company ...

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...

(Bloomberg) -- Novo Nordisk A/S shares plunged the most since December after another disappointment for the drugmaker’s next-generation shot CagriSema. The medicine helped patients with diabetes ...

The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss ...

After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...